Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2018
At a glance
- Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 19 Jun 2018 Number of treatment arm has been changed from 3 to 4. Extended Treatment Arm IV arm has been added into the treatment.
- 19 Jun 2018 Planned number of patients changed from 32 to 66.
- 19 Jun 2018 Planned End Date changed from 30 Sep 2019 to 1 Sep 2019.